Personalized medicine in gastric cancer: Where are we and where are we going?
|
摘要
Despite improvements in adjuvant therapies for gastric cancer in recent years, the disease is characterized by high recurrence rates and a dismal prognosis. The major improvement in the treatment of recurrent or metastatic gastric cancer in recent years has been the incorporation of trastuzumab, a monoclonal antibody that inhibits human epidermal growth factor receptor 2(HER2) heterodimerization, after the demonstrated predictive value of the overexpression and/or amplification of this receptor. Beyond HER2, other genetic abnormalities have been identified, and these mutations may be targetable by tyrosine kinase inhibitors or monoclonal antibodies. The demonstration of four distinct molecular subtypes of gastric cancer by the Cancer Genome Atlas study highlight the enormous heterogeneity of the disease and its complex interplay between genetic and epigenetic alterations and provide a roadmap to implement genome-guided personalized therapy in gastric cancer. In the present review, we aim to discuss, from a clinical point of view, the genomic landscape of gastric cancer described in recent studies, the therapeutic insights derived from these findings, and the clinical trials that have been conducted and those in progress that take into account tailored therapies for gastric cancer.
Despite improvements in adjuvant therapies for gastric cancer in recent years, the disease is characterized by high recurrence rates and a dismal prognosis. The major improvement in the treatment of recurrent or metastatic gastric cancer in recent years has been the incorporation of trastuzumab, a monoclonal antibody that inhibits human epidermal growth factor receptor 2(HER2) heterodimerization, after the demonstrated predictive value of the overexpression and/or amplification of this receptor. Beyond HER2, other genetic abnormalities have been identified, and these mutations may be targetable by tyrosine kinase inhibitors or monoclonal antibodies. The demonstration of four distinct molecular subtypes of gastric cancer by the Cancer Genome Atlas study highlight the enormous heterogeneity of the disease and its complex interplay between genetic and epigenetic alterations and provide a roadmap to implement genome-guided personalized therapy in gastric cancer. In the present review, we aim to discuss, from a clinical point of view, the genomic landscape of gastric cancer described in recent studies, the therapeutic insights derived from these findings, and the clinical trials that have been conducted and those in progress that take into account tailored therapies for gastric cancer.
Despite improvements in adjuvant therapies for gastric cancer in recent years, the disease is characterized by high recurrence rates and a dismal prognosis. The major improvement in the treatment of recurrent or metastatic gastric cancer in recent years has been the incorporation of trastuzumab, a monoclonal antibody that inhibits human epidermal growth factor receptor 2(HER2) heterodimerization, after the demonstrated predictive value of the overexpression and/or amplification of this receptor. Beyond HER2, other genetic abnormalities have been identified, and these mutations may be targetable by tyrosine kinase inhibitors or monoclonal antibodies. The demonstration of four distinct molecular subtypes of gastric cancer by the Cancer Genome Atlas study highlight the enormous heterogeneity of the disease and its complex interplay between genetic and epigenetic alterations and provide a roadmap to implement genome-guided personalized therapy in gastric cancer. In the present review, we aim to discuss, from a clinical point of view, the genomic landscape of gastric cancer described in recent studies, the therapeutic insights derived from these findings, and the clinical trials that have been conducted and those in progress that take into account tailored therapies for gastric cancer.
引文
1 Torre LA,Bray F,Siegel RL,Ferlay J,Lortet-Tieulent J,Jemal A.Global cancer statistics,2012.CA Cancer J Clin 2015;65:87-108[PMID:25651787 DOI:10.3322/caac.21262]
2 D’Angelica M,Gonen M,Brennan MF,Turnbull AD,Bains M,Karpeh MS.Patterns of initial recurrence in completely resected gastric adenocarcinoma.Ann Surg 2004;240:808-816[PMID:15492562]
3 Yoo CH,Noh SH,Shin DW,Choi SH,Min JS.Recurrence following curative resection for gastric carcinoma.Br J Surg 2000;87:236-242[PMID:10671934]
4 Ajani JA,Rodriguez W,Bodoky G,Moiseyenko V,Lichinitser M,Gorbunova V,Vynnychenko I,Garin A,Lang I,Falcon S.Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study:the FLAGS trial.J Clin Oncol 2010;28:1547-1553[PMID:20159816 DOI:10.1200/JCO.2009.25.4706]
5 Bang YJ,Van Cutsem E,Feyereislova A,Chung HC,Shen L,Sawaki A,Lordick F,Ohtsu A,Omuro Y,Satoh T,Aprile G,Kulikov E,Hill J,Lehle M,Rüschoff J,Kang YK.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(To GA):a phase 3,open-label,randomised controlled trial.Lancet 2010;376:687-697[PMID:20728210DOI:10.1016/S0140-6736(10)61121-X]
6 Cancer Genome Atlas Research Network.Comprehensive molecular characterization of gastric adenocarcinoma.Nature2014;513:202-209[PMID:25079317 DOI:10.1038/nature13480]
7 Songun I,Putter H,Kranenbarg EM,Sasako M,van de Velde CJ.Surgical treatment of gastric cancer:15-year follow-up results of the randomised nationwide Dutch D1D2 trial.Lancet Oncol2010;11:439-449[PMID:20409751 DOI:10.1016/S1470-2045(10)70070-X]
8 Smalley SR,Benedetti JK,Haller DG,Hundahl SA,Estes NC,Ajani JA,Gunderson LL,Goldman B,Martenson JA,Jessup JM,Stemmermann GN,Blanke CD,Macdonald JS.Updated analysis of SWOG-directed intergroup study 0116:a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.J Clin Oncol 2012;30:2327-2333[PMID:22585691 DOI:10.1200/JCO.2011.36.7136]
9 Park SH,Sohn TS,Lee J,Lim do H,Hong ME,Kim KM,Sohn I,Jung SH,Choi MG,Lee JH,Bae JM,Kim S,Kim ST,Park JO,Park YS,Lim HY,Kang WK.Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer:Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial,Including Survival and Subset Analyses.J Clin Oncol 2015;33:3130-3136[PMID:25559811 DOI:10.1200/JCO.2014.58.3930]
10 Cunningham D,Allum WH,Stenning SP,Thompson JN,Van de Velde CJ,Nicolson M,Scarffe JH,Lofts FJ,Falk SJ,Iveson TJ,Smith DB,Langley RE,Verma M,Weeden S,Chua YJ.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.N Engl J Med 2006;355:11-20[PMID:16822992 DOI:10.1056/NEJMoa055531]
11 Sasako M,Sakuramoto S,Katai H,Kinoshita T,Furukawa H,Yamaguchi T,Nashimoto A,Fujii M,Nakajima T,Ohashi Y.Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.J Clin Oncol 2011;29:4387-4393[PMID:22010012 DOI:10.1200/JCO.2011.36.5908]
12 Bang YJ,Kim YW,Yang HK,Chung HC,Park YK,Lee KH,Lee KW,Kim YH,Noh SI,Cho JY,Mok YJ,Kim YH,Ji J,Yeh TS,Button P,Sirzén F,Noh SH.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC):a phase 3open-label,randomised controlled trial.Lancet 2012;379:315-321[PMID:22226517 DOI:10.1016/S0140-6736(11)61873-4]
13 Vanhoefer U,Rougier P,Wilke H,Ducreux MP,Lacave AJ,Van Cutsem E,Planker M,Santos JG,Piedbois P,Paillot B,Bodenstein H,Schmoll HJ,Bleiberg H,Nordlinger B,Couvreur ML,Baron B,Wils JA.Final results of a randomized phase III trial of sequential high-dose methotrexate,fluorouracil,and doxorubicin versus etoposide,leucovorin,and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer:A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.J Clin Oncol2000;18:2648-2657[PMID:10894863]
14 Cunningham D,O kines A F,Ashley S.Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med 2010;362:858-859[PMID:20200397 DOI:10.1056/NEJMc0911925]
15 Van Cutsem E,Moiseyenko VM,Tjulandin S,Majlis A,Constenla M,Boni C,Rodrigues A,Fodor M,Chao Y,Voznyi E,Risse ML,Ajani JA.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group.J Clin Oncol 2006;24:4991-4997[PMID:17075117 DOI:10 .1200/JCO.2006.06.8429]
16 Hironaka S,Ueda S,Yasui H,Nishina T,Tsuda M,Tsumura T,Sugimoto N,Shimodaira H,Tokunaga S,Moriwaki T,Esaki T,Nagase M,Fujitani K,Yamaguchi K,Ura T,Hamamoto Y,Morita S,Okamoto I,Boku N,Hyodo I.Randomized,open-label,phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum:WJOG 4007 trial.J Clin Oncol 2013;31:4438-4444[PMID:24190112 DOI:10.1200/JCO.2012.48.5805]
17 Ford HE,Marshall A,Bridgewater JA,Janowitz T,Coxon FY,Wadsley J,Mansoor W,Fyfe D,Madhusudan S,Middleton GW,Swinson D,Falk S,Chau I,Cunningham D,Kareclas P,Cook N,Blazeby JM,Dunn JA.Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma(COUGAR-02):an open-label,phase 3 randomised controlled trial.Lancet Oncol 2014;15:78-86[PMID:24332238 DOI:10.1016/S1470-2045(13)70549-7]
18 Fuchs CS,Tomasek J,Yong CJ,Dumitru F,Passalacqua R,Goswami C,Safran H,dos Santos LV,Aprile G,Ferry DR,Melichar B,Tehfe M,Topuzov E,Zalcberg JR,Chau I,Campbell W,Sivanandan C,Pikiel J,Koshiji M,Hsu Y,Liepa AM,Gao L,Schwartz JD,Tabernero J.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD):an international,randomised,multicentre,placebo-controlled,phase 3 trial.Lancet 2014;383:31-39[PMID:24094768 DOI:10.1016/S0140-6736(13)61719-5]
19 Wilke H,Muro K,Van Cutsem E,Oh SC,Bodoky G,Shimada Y,Hironaka S,Sugimoto N,Lipatov O,Kim TY,Cunningham D,Rougier P,Komatsu Y,Ajani J,Emig M,Carlesi R,Ferry D,Chandrawansa K,Schwartz JD,Ohtsu A.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(RAINBOW):a double-blind,randomised phase3 trial.Lancet Oncol 2014;15:1224-1235[PMID:25240821 DOI:10 .1016/S1470-2045(14)70420-6]
20 Fuchs CS,Mayer RJ.Gastric carcinoma.N Engl J Med 1995;333:32-41[PMID:7776992 DOI:10.1056/NEJM199507063330107]
21 Parsonnet J,Friedman GD,Orentreich N,Vogelman H.Risk for gastric cancer in people with Cag A positive or Cag A negative Helicobacter pylori infection.Gut 1997;40:297-301[PMID:9135515]
22 Chow WH,Blot WJ,Vaughan TL,Risch HA,Gammon MD,Stanford JL,Dubrow R,Schoenberg JB,Mayne ST,Farrow DC,Ahsan H,West AB,Rotterdam H,Niwa S,Fraumeni JF.Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia.J Natl Cancer Inst 1998;90:150-155[PMID:9450576]
23 Lagergren J,Bergstr?m R,Lindgren A,Nyrén O.Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.N Engl J Med 1999;340:825-831[PMID:10080844 DOI:10.1056/NEJM199903183401101]
24 Nicholson RI,Gee JM,Harper ME.EGFR and cancer prognosis.Eur J Cancer 2001;37 Suppl 4:S9-S15[PMID:11597399]
25 Hudis CA.Trastuzumab--mechanism of action and use in clinical practice.N Engl J Med 2007;357:39-51[PMID:17611206 DOI:10 .1056/NEJMra043186]
26 Sithanandam G,Anderson LM.The ERBB3 receptor in cancer and cancer gene therapy.Cancer Gene Ther 2008;15:413-448[PMID:18404164 DOI:10.1038/cgt.2008.15]
27 Gu J,Zheng L,Wang Y,Zhu M,Wang Q,Li X.Prognostic significance of HER2 expression based on trastuzumab for gastric cancer(To GA)criteria in gastric cancer:an updated meta-analysis.Tumour Biol 2014;35:5315-5321[PMID:24557541 DOI:10 .1007/s13277-014-1693-7]
28 Chen C,Yang JM,Hu TT,Xu TJ,Yan G,Hu SL,Wei W,Xu WP.Prognostic role of human epidermal growth factor receptor in gastric cancer:a systematic review and meta-analysis.Arch Med Res 2013;44:380-389[PMID:23871709 DOI:10.1016/j.arcmed.2013.07.001]
29 Liang JW,Zhang JJ,Zhang T,Zheng ZC.Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer:a meta-analysis of the literature.Tumour Biol 2014;35:4849-4858[PMID:24449506 DOI:10.1007/s13277-014-1636-3]
30 Baselga J,Cortés J,Kim SB,Im SA,Hegg R,Im YH,Roman L,Pedrini JL,Pienkowski T,Knott A,Clark E,Benyunes MC,Ross G,Swain SM.Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.N Engl J Med 2012;366:109-119[PMID:22149875 DOI:10.1056/NEJMoa1113216]
31 Kang YK,Rha SY,Tassone P,Barriuso J,Yu R,Szado T,Garg A,Bang YJ.A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab,capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.Br J Cancer 2014;111:660-666[PMID:24960402 DOI:10.1038/bjc.2014.356]
32 Satoh T,Xu RH,Chung HC,Sun GP,Doi T,Xu JM,Tsuji A,Omuro Y,Li J,Wang JW,Miwa H,Qin SK,Chung IJ,Yeh KH,Feng JF,Mukaiyama A,Kobayashi M,Ohtsu A,Bang YJ.Lapatinib plus paclitaxel versus paclitaxel alone in the secondline treatment of HER2-amplified advanced gastric cancer in Asian populations:Ty TAN--a randomized,phase III study.J Clin Oncol 2014;32:2039-2049[PMID:24868024 DOI:10.1200/JCO.2013.53.6136]
33 Hecht J,Bang Y,Qin S,Chung H,Xu J,Park J,Jeziorski K,Shparyk Y,Hoff P,Sobrero A,Salman P,Li J,Protsenko S,Buyse M,Afenjar K,Kaneko T,Kemner A,Santillana S,Press M,Slamon D.Lapatinib in combination with capecitabine plus oxaliplatin(Cape Ox)in HER2-positive advanced or metastatic gastric,esophageal,or gastroesophageal adenocarcinoma(AC):The TRIO-013/LOGi C Trial.J Clin Oncol 2013;31(Suppl 18):4001
34 Jácome AA,Wohnrath DR,Scapulatempo Neto C,Carneseca EC,Serrano SV,Viana LS,Nunes JS,Martinez EZ,Santos JS.Prognostic value of epidermal growth factor receptors in gastric cancer:a survival analysis by Weibull model incorporating longterm survivors.Gastric Cancer 2014;17:76-86[PMID:23455716DOI:10.1007/s10120-013-0236-z]
35 Begnami MD,Fukuda E,Fregnani JH,Nonogaki S,Montagnini AL,da Costa WL,Soares FA.Prognostic implications of altered human epidermal growth factor receptors(HERs)in gastric carcinomas:HER2 and HER3 are predictors of poor outcome.J Clin Oncol 2011;29:3030-3036[PMID:21709195 DOI:10.1200/JCO.2010.33.6313]
36 Kim MA,Lee HS,Lee HE,Jeon YK,Yang HK,Kim WH.EGFR in gastric carcinomas:prognostic significance of protein overexpression and high gene copy number.Histopathology 2008;52:738-746[PMID:18397279 DOI:10.1111/j.1365-2559.2008.03021.x]
37 Lordick F,Kang YK,Chung HC,Salman P,Oh SC,Bodoky G,Kurteva G,Volovat C,Moiseyenko VM,Gorbunova V,Park JO,Sawaki A,Celik I,G?tte H,MelezínkováH,Moehler M.Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer(EXPAND):a randomised,open-label phase 3 trial.Lancet Oncol 2013;14:490-499[PMID:23594786 DOI:10.1016/S1470-2045(13)70102-5]
38 Waddell T,Chau I,Cunningham D,Gonzalez D,Okines AF,Okines C,Wotherspoon A,Saffery C,Middleton G,Wadsley J,Ferry D,Mansoor W,Crosby T,Coxon F,Smith D,Waters J,Iveson T,Falk S,Slater S,Peckitt C,Barbachano Y.Epirubicin,oxaliplatin,and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer(REAL3):a randomised,open-label phase 3 trial.Lancet Oncol 2013;14:481-489[PMID:23594787 DOI:10.1016/S1470-2045(13)70096-2]
39 Kim Y,Sasaki Y,Lee K,Rha S,Park S,Boku N,Komatsu Y,Kim T,Kim S,Sakata Y.Randomized phase II study of nimotuzumab,an anti-EGFR antibody,plus irinotecan in patients with 5-fluorouracilbased regimen-refractory advanced or recurrent gastric cancer in Korea and Japan:Preliminary results.J Clin Oncol 2011;29(suppl4);87
40 Dragovich T,Mc Coy S,Fenoglio-Preiser CM,Wang J,Benedetti JK,Baker AF,Hackett CB,Urba SG,Zaner KS,Blanke CD,Abbruzzese JL.Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas:SWOG 0127.J Clin Oncol 2006;24:4922-4927[PMID:17050876 DOI:10.1200/JCO.2006.07.1316]
41 Ferrara N,Gerber HP,Le Couter J.The biology of VEGF and its receptors.Nat Med 2003;9:669-676[PMID:12778165 DOI:10 .1038/nm0603-669]
42 Lieto E,Ferraraccio F,Orditura M,Castellano P,Mura AL,Pinto M,Zamboli A,De Vita F,Galizia G.Expression of vascular endothelial growth factor(VEGF)and epidermal growth factor receptor(EGFR)is an independent prognostic indicator of worse outcome in gastric cancer patients.Ann Surg Oncol 2008;15:69-79[PMID:17896140 DOI:10.1245/s10434-007-9596-0]
43 Cabuk D,Basaran G,Celikel C,Dane F,Yumuk PF,Iyikesici MS,Ekenel M,Turhal NS.Vascular endothelial growth factor,hypoxia-inducible factor 1 alpha and CD34 expressions in earlystage gastric tumors:relationship with pathological factors and prognostic impact on survival.Oncology 2007;72:111-117[PMID:18025805 DOI:10.1159/111118]
44 Hurwitz H,Fehrenbacher L,Novotny W,Cartwright T,Hainsworth J,Heim W,Berlin J,Baron A,Griffing S,Holmgren E,Ferrara N,Fyfe G,Rogers B,Ross R,Kabbinavar F.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer.N Engl J Med 2004;350:2335-2342[PMID:15175435 DOI:10.1056/NEJMoa032691]
45 Sandler A,Gray R,Perry MC,Brahmer J,Schiller JH,Dowlati A,Lilenbaum R,Johnson DH.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med 2006;355:2542-2550[PMID:17167137 DOI:10.1056/NEJMoa061884]
46 Miller K,Wang M,Gralow J,Dickler M,Cobleigh M,Perez EA,Shenkier T,Cella D,Davidson NE.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.N Engl J Med 2007;357:2666-2676[PMID:18160686 DOI:10.1056/NEJMoa072113]
47 Friedman HS,Prados MD,Wen PY,Mikkelsen T,Schiff D,Abrey LE,Yung WK,Paleologos N,Nicholas MK,Jensen R,Vredenburgh J,Huang J,Zheng M,Cloughesy T.Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.J Clin Oncol 2009;27:4733-4740[PMID:19720927 DOI:10 .1200/JCO.2008.19.8721]
48 Burger RA,Brady MF,Bookman MA,Fleming GF,Monk BJ,Huang H,Mannel RS,Homesley HD,Fowler J,Greer BE,Boente M,Birrer MJ,Liang SX.Incorporation of bevacizumab in the primary treatment of ovarian cancer.N Engl J Med 2011;365:2473-2483[PMID:22204724 DOI:10.1056/NEJMoa1104390]
49 Perren TJ,Swart AM,Pfisterer J,Ledermann JA,Pujade-Lauraine E,Kristensen G,Carey MS,Beale P,Cervantes A,Kurzeder C,du Bois A,Sehouli J,Kimmig R,St?hle A,Collinson F,Essapen S,Gourley C,Lortholary A,Selle F,Mirza MR,Leminen A,Plante M,Stark D,Qian W,Parmar MK,Oza AM.A phase 3trial of bevacizumab in ovarian cancer.N Engl J Med 2011;365:2484-2496[PMID:22204725 DOI:10.1056/NEJMoa1103799]
50 Tewari KS,Sill MW,Long HJ,Penson RT,Huang H,Ramondetta LM,Landrum LM,Oaknin A,Reid TJ,Leitao MM,Michael HE,Monk BJ.Improved survival with bevacizumab in advanced cervical cancer.N Engl J Med 2014;370:734-743[PMID:24552320 DOI:10.1056/NEJMoa1309748]
51 Shah MA,Ramanathan RK,Ilson DH,Levnor A,D’Adamo D,O’Reilly E,Tse A,Trocola R,Schwartz L,Capanu M,Schwartz GK,Kelsen DP.Multicenter phase II study of irinotecan,cisplatin,and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.J Clin Oncol 2006;24:5201-5206[PMID:17114652 DOI:10.1200/JCO.2006.08.0887]
52 Ohtsu A,Shah MA,Van Cutsem E,Rha SY,Sawaki A,Park SR,Lim HY,Yamada Y,Wu J,Langer B,Starnawski M,Kang YK.Bevacizumab in combination with chemotherapy as firstline therapy in advanced gastric cancer:a randomized,doubleblind,placebo-controlled phase III study.J Clin Oncol 2011;29:3968-3976[PMID:21844504 DOI:10.1200/JCO.2011.36.2236]
53 Yoon H,Johanna C,Braiteh F,Firdaus I,Philip P,Cohn A,Lewis N,Anderson D,Arrowsmith E,Schwartz J,Xu Y,Koshiji M,Alberts S,Wainberg Z.Ramucirumab(RAM)plus FOLFOX as front-line therapy(Rx)for advanced gastric or esophageal adenocarcinoma(GE-AC):Randomized,double-blind,multicenter phase 2 trial.J Clin Oncol 2014;32(Suppl 15):4004
54 Qin S.Phase III study of apatinib in advanced gastric cancer:A randomized,double-blind,placebo-controlled trial.J Clin Oncol2014;32(Suppl 15):4003
55 Jia S,Liu Z,Zhang S,Liu P,Zhang L,Lee SH,Zhang J,Signoretti S,Loda M,Roberts TM,Zhao JJ.Essential roles of PI(3)K-p110beta in cell growth,metabolism and tumorigenesis.Nature 2008;454:776-779[PMID:18594509 DOI:10.1038/nature07091]
56 Byun DS,Cho K,Ryu BK,Lee MG,Park JI,Chae KS,Kim HJ,Chi SG.Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.Int J Cancer 2003;104:318-327[PMID:12569555 DOI:10.1002/ijc.10962]
57 Li VS,Wong CW,Chan TL,Chan AS,Zhao W,Chu KM,So S,Chen X,Yuen ST,Leung SY.Mutations of PIK3CA in gastric adenocarcinoma.BMC Cancer 2005;5:29[PMID:15784156DOI:10.1186/1471-2407-5-29]
58 Velho S,Oliveira C,Ferreira A,Ferreira AC,Suriano G,Schwartz S,Duval A,Carneiro F,Machado JC,Hamelin R,Seruca R.The prevalence of PIK3CA mutations in gastric and colon cancer.Eur J Cancer 2005;41:1649-1654[PMID:15994075 DOI:10.1016/j.ejca.2005.04.022]
59 Zhou J,Chen GB,Tang YC,Sinha RA,Wu Y,Yap CS,Wang G,Hu J,Xia X,Tan P,Goh LK,Yen PM.Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library.BMC Med Genomics 2012;5:34[PMID:22876838 DOI:10 .1186/1755-8794-5-34]
60 Lang SA,Gaumann A,Koehl GE,Seidel U,Bataille F,Klein D,Ellis LM,Bolder U,Hofstaedter F,Schlitt HJ,Geissler EK,Stoeltzing O.Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.Int J Cancer 2007;120:1803-1810[PMID:17230506 DOI:10.1002/ijc.22442]
61 Ohtsu A,Ajani JA,Bai YX,Bang YJ,Chung HC,Pan HM,Sahmoud T,Shen L,Yeh KH,Chin K,Muro K,Kim YH,Ferry D,Tebbutt NC,Al-Batran SE,Smith H,Costantini C,Rizvi S,Lebwohl D,Van Cutsem E.Everolimus for previously treated advanced gastric cancer:results of the randomized,double-blind,phase III GRANITE-1 study.J Clin Oncol 2013;31:3935-3943[PMID:24043745 DOI:10.1200/JCO.2012.48.3552]
62 Blume-Jensen P,Hunter T.Oncogenic kinase signalling.Nature2001;411:355-365[PMID:11357143 DOI:10.1038/35077225]
63 Xie L,Su X,Zhang L,Yin X,Tang L,Zhang X,Xu Y,Gao Z,Liu K,Zhou M,Gao B,Shen D,Zhang L,Ji J,Gavine PR,Zhang J,Kilgour E,Zhang X,Ji Q.FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.Clin Cancer Res 2013;19:2572-2583[PMID:23493349DOI:10.1158/1078-0432.CCR-12-3898]
64 Su X,Zhan P,Gavine PR,Morgan S,Womack C,Ni X,Shen D,Bang YJ,Im SA,Ho Kim W,Jung EJ,Grabsch HI,Kilgour E.FGFR2 amplification has prognostic significance in gastric cancer:results from a large international multicentre study.Br J Cancer2014;110:967-975[PMID:24457912 DOI:10.1038/bjc.2013.802]
65 Jung EJ,Jung EJ,Min SY,Kim MA,Kim WH.Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma.Hum Pathol 2012;43:1559-1566[PMID:22440694 DOI:10.1016/j.humpath.2011.12.002]
66 Gozgit JM,Wong MJ,Moran L,Wardwell S,Mohemmad QK,Narasimhan NI,Shakespeare WC,Wang F,Clackson T,Rivera VM.Ponatinib(AP24534),a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.Mol Cancer Ther 2012;11:690-699[PMID:22238366DOI:10.1158/1535-7163.MCT-11-0450]
67 Deng N,Goh LK,Wang H,Das K,Tao J,Tan IB,Zhang S,Lee M,Wu J,Lim KH,Lei Z,Goh G,Lim QY,Tan AL,Sin Poh DY,Riahi S,Bell S,Shi MM,Linnartz R,Zhu F,Yeoh KG,Toh HC,Yong WP,Cheong HC,Rha SY,Boussioutas A,Grabsch H,Rozen S,Tan P.A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.Gut 2012;61:673-684[PMID:22315472 DOI:10.1136/gutjnl-2011-301839]
68 Bang YJ,Van Cutsem E,Mansoor W,Petty R,Chao Y,Cunningham D,Ferry D,Landers D,Stockman P,Smith N,Geh C,Kilgour E.A randomized,open-label phase II study of AZD4547(AZD)versus Paclitaxel(P)in previously treated patients with advanced gastric cancer(AGC)with Fibroblast Growth Factor Receptor 2(FGFR2)polysomy or gene amplification(amp):SHINE study.J Clin Oncol 2015;33(Suppl 20):4014
69 Kiyose S,Nagura K,Tao H,Igarashi H,Yamada H,Goto M,Maeda M,Kurabe N,Suzuki M,Tsuboi M,Kahyo T,Shinmura K,Hattori N,Sugimura H.Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization.Pathol Int 2012;62:477-484[PMID:22691185 DOI:10.1111/j.1440-1827.2012.02832.x]
70 Lennerz JK,Kwak EL,Ackerman A,Michael M,Fox SB,Bergethon K,Lauwers GY,Christensen JG,Wilner KD,Haber DA,Salgia R,Bang YJ,Clark JW,Solomon BJ,Iafrate AJ.MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.J Clin Oncol 2011;29:4803-4810[PMID:22042947DOI:10.1200/JCO.2011.35.4928]
71 Shah MA,Wainberg ZA,Catenacci DV,Hochster HS,Ford J,Kunz P,Lee FC,Kallender H,Cecchi F,Rabe DC,Keer H,Martin AM,Liu Y,Gagnon R,Bonate P,Liu L,Gilmer T,Bottaro DP.Phase II study evaluating 2 dosing schedules of oral foretinib(GSK1363089),c MET/VEGFR2 inhibitor,in patients with metastatic gastric cancer.PLo S One 2013;8:e54014[PMID:23516391 DOI:10.1371/journal.pone.0054014]
72 Shah M,Bang Y,Lordick F,Tabernero J,Chen M,Hack S,Phan S,Shames D,Cunningham D.METGastric:A phase III study of onartuzumab plus m FOLFOX6 in patients with metastatic HER2-negative(HER2-)and MET-positive(MET)adenocarcinoma of the stomach or gastroesophageal junction(GEC).J Clin Oncol2015;33(Suppl 15):4012
73 Iveson T,Donehower RC,Davidenko I,Tjulandin S,Deptala A,Harrison M,Nirni S,Lakshmaiah K,Thomas A,Jiang Y,Zhu M,Tang R,Anderson A,Dubey S,Oliner KS,Loh E.Rilotumumab in combination with epirubicin,cisplatin,and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma:an open-label,dose de-escalation phase 1b study and a double-blind,randomised phase 2 study.Lancet Oncol 2014;15:1007-1018[PMID:24965569 DOI:10.1016/S1470-2045(14)70023-3]
74 Cunningham D,Tebbutt N,Davidenko I,Murad M,Al-Batran S,Ilson D,Tjulandin S,Gotovkin E,Karaszewska B,Bondarenko I,Tejani M,Udrea A,Tehfe M,Baker N,Oliner K,Zhang Y,Hoang T,R S,Catenacci D.Phase III,randomized,double-blind,multicenter,placebo(P)-controlled trial of rilotumumab(R)plus epirubicin,cisplatin and capecitabine(ECX)as first-line therapy in patients(pts)with advanced MET-positive(pos)gastric or gastroesophageal junction(G/GEJ)cancer:RILOMET-1 study.J Clin Oncol 2015;33 (Suppl 15):4000
75 Malka D,Castan F,Francois E,Bouche O,Bennouna J,Ghiringhelli F,De La Fouchardiere C,Borg C,Samalin E,Bachet J,Raoul J,Cvitkovic F,Miglianico L,Bengrine-Lefevre L,Dahan L,Lecaille C,Aparicio T,Perrier H,Gourgou S,Taieb J.FOLFOX alone or combined to rilotumumab or panitumumab as firstline treatment in patients(pts)with advanced gastroesophageal adenocarcinoma(AGEA):An open-label,randomized phase II trial(PRODIGE 17 ACCORD 20 MEGA).J Clin Oncol 2015;33(Suppl15):4016
76 Kang YK,Muro K,Ryu MH,Yasui H,Nishina T,Ryoo BY,Kamiya Y,Akinaga S,Boku N.A phase II trial of a selective c-Met inhibitor tivantinib(ARQ 197)monotherapy as a second-or thirdline therapy in the patients with metastatic gastric cancer.Invest New Drugs 2014;32:355-361[PMID:24337769 DOI:10.1007/s10637-013-0057-2]
77 Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer 2012;12:252-264[PMID:22437870 DOI:10.1038/nrc3239]
78 Hodi FS,O’Day SJ,Mc Dermott DF,Weber RW,Sosman JA,Haanen JB,Gonzalez R,Robert C,Schadendorf D,Hassel JC,Akerley W,van den Eertwegh AJ,Lutzky J,Lorigan P,Vaubel JM,Linette GP,Hogg D,Ottensmeier CH,LebbéC,Peschel C,Quirt I,Clark JI,Wolchok JD,Weber JS,Tian J,Yellin MJ,Nichol GM,Hoos A,Urba WJ.Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med 2010;363:711-723[PMID:20525992 DOI:10.1056/NEJMoa1003466]
79 Hamid O,Robert C,Daud A,Hodi FS,Hwu WJ,Kefford R,Wolchok JD,Hersey P,Joseph RW,Weber JS,Dronca R,Gangadhar TC,Patnaik A,Zarour H,Joshua AM,Gergich K,Elassaiss-Schaap J,Algazi A,Mateus C,Boasberg P,Tumeh PC,Chmielowski B,Ebbinghaus SW,Li XN,Kang SP,Ribas A.Safety and tumor responses with lambrolizumab(anti-PD-1)in melanoma.N Engl J Med 2013;369:134-144[PMID:23724846DOI:10.1056/NEJMoa1305133]
80 Robert C,Long GV,Brady B,Dutriaux C,Maio M,Mortier L,Hassel JC,Rutkowski P,Mc Neil C,Kalinka-Warzocha E,Savage KJ,Hernberg MM,LebbéC,Charles J,Mihalcioiu C,ChiarionSileni V,Mauch C,Cognetti F,Arance A,Schmidt H,Schadendorf D,Gogas H,Lundgren-Eriksson L,Horak C,Sharkey B,Waxman IM,Atkinson V,Ascierto PA.Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med 2015;372:320-330[PMID:25399552 DOI:10.1056/NEJMoa1412082]
81 Qing Y,Li Q,Ren T,Xia W,Peng Y,Liu GL,Luo H,Yang YX,Dai XY,Zhou SF,Wang D.Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer.Drug Des Devel Ther 2015;9:901-909[PMID:25733810 DOI:10 .2147/DDDT.S75152]
82 Wu C,Zhu Y,Jiang J,Zhao J,Zhang XG,Xu N.Immunohistochemical localization of programmed death-1 ligand-1(PD-L1)in gastric carcinoma and its clinical significance.Acta Histochem 2006;108:19-24[PMID:16530813 DOI:10.1016/j.acthis.2006.01.003]
83 Sun J,Xu K,Wu C,Wang Y,Hu Y,Zhu Y,Chen Y,Shi Q,Yu G,Zhang X.PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies.Tissue Antigens 2007;69:19-27[PMID:17212704 DOI:10.1111/j.1399-0039.2006.00701.x]
84 Muro K,Bang Y,Shankaran V,Geva R,Catenacci D,Gupta S,Eder J,Berger R,Gonzalez E,Pulini J,Ray A,Dolled-Filhart M,Emancipator K,Pathiraja K,Shu X,Koshiji M,Cheng J,Chung H.A phase Ib study of pembrolizumab(Pembro;MK-3475)in patients(Pts)with advanced gastric cancer.Ann Oncol 2014;25:1-41[DOI:10.1093/annonc/mdu438]
85 Kralovics R,Passamonti F,Buser AS,Teo SS,Tiedt R,Passweg JR,Tichelli A,Cazzola M,Skoda RC.A gain-of-function mutation of JAK2 in myeloproliferative disorders.N Engl J Med 2005;352:1779-1790[PMID:15858187 DOI:10.1056/NEJMoa051113]
86 Levine RL,Pardanani A,Tefferi A,Gilliland DG.Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.Nat Rev Cancer 2007;7:673-683[PMID:17721432 DOI:10.1038/nrc2210]
87 Judd LM,Menheniott TR,Ling H,Jackson CB,Howlett M,Kalantzis A,Priebe W,Giraud AS.Inhibition of the JAK2/STAT3pathway reduces gastric cancer growth in vitro and in vivo.PLo S One 2014;9:e95993[PMID:24804649 DOI:10.1371/journal.pone.0095993]
88 Ledermann J,Harter P,Gourley C,Friedlander M,Vergote I,Rustin G,Scott C,Meier W,Shapira-Frommer R,Safra T,Matei D,Macpherson E,Watkins C,Carmichael J,Matulonis U.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.N Engl J Med 2012;366:1382-1392[PMID:22452356 DOI:10 .1056/NEJMoa1105535]
89 Oza AM,Cibula D,Benzaquen AO,Poole C,Mathijssen RH,Sonke GS,Colombo N,?pa?ek J,Vuylsteke P,Hirte H,Mahner S,Plante M,Schmalfeldt B,Mackay H,Rowbottom J,Lowe ES,Dougherty B,Barrett JC,Friedlander M.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer:a randomised phase 2 trial.Lancet Oncol 2015;16:87-97[PMID:25481791 DOI:10.1016/S1470-2045(14)71135-0]
90 O’Shaughnessy J,Osborne C,Pippen JE,Yoffe M,Patt D,Rocha C,Koo IC,Sherman BM,Bradley C.Iniparib plus chemotherapy in metastatic triple-negative breast cancer.N Engl J Med 2011;364:205-214[PMID:21208101 DOI:10.1056/NEJMoa1011418]
2 D’Angelica M,Gonen M,Brennan MF,Turnbull AD,Bains M,Karpeh MS.Patterns of initial recurrence in completely resected gastric adenocarcinoma.Ann Surg 2004;240:808-816[PMID:15492562]
3 Yoo CH,Noh SH,Shin DW,Choi SH,Min JS.Recurrence following curative resection for gastric carcinoma.Br J Surg 2000;87:236-242[PMID:10671934]
4 Ajani JA,Rodriguez W,Bodoky G,Moiseyenko V,Lichinitser M,Gorbunova V,Vynnychenko I,Garin A,Lang I,Falcon S.Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study:the FLAGS trial.J Clin Oncol 2010;28:1547-1553[PMID:20159816 DOI:10.1200/JCO.2009.25.4706]
5 Bang YJ,Van Cutsem E,Feyereislova A,Chung HC,Shen L,Sawaki A,Lordick F,Ohtsu A,Omuro Y,Satoh T,Aprile G,Kulikov E,Hill J,Lehle M,Rüschoff J,Kang YK.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(To GA):a phase 3,open-label,randomised controlled trial.Lancet 2010;376:687-697[PMID:20728210DOI:10.1016/S0140-6736(10)61121-X]
6 Cancer Genome Atlas Research Network.Comprehensive molecular characterization of gastric adenocarcinoma.Nature2014;513:202-209[PMID:25079317 DOI:10.1038/nature13480]
7 Songun I,Putter H,Kranenbarg EM,Sasako M,van de Velde CJ.Surgical treatment of gastric cancer:15-year follow-up results of the randomised nationwide Dutch D1D2 trial.Lancet Oncol2010;11:439-449[PMID:20409751 DOI:10.1016/S1470-2045(10)70070-X]
8 Smalley SR,Benedetti JK,Haller DG,Hundahl SA,Estes NC,Ajani JA,Gunderson LL,Goldman B,Martenson JA,Jessup JM,Stemmermann GN,Blanke CD,Macdonald JS.Updated analysis of SWOG-directed intergroup study 0116:a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.J Clin Oncol 2012;30:2327-2333[PMID:22585691 DOI:10.1200/JCO.2011.36.7136]
9 Park SH,Sohn TS,Lee J,Lim do H,Hong ME,Kim KM,Sohn I,Jung SH,Choi MG,Lee JH,Bae JM,Kim S,Kim ST,Park JO,Park YS,Lim HY,Kang WK.Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer:Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial,Including Survival and Subset Analyses.J Clin Oncol 2015;33:3130-3136[PMID:25559811 DOI:10.1200/JCO.2014.58.3930]
10 Cunningham D,Allum WH,Stenning SP,Thompson JN,Van de Velde CJ,Nicolson M,Scarffe JH,Lofts FJ,Falk SJ,Iveson TJ,Smith DB,Langley RE,Verma M,Weeden S,Chua YJ.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.N Engl J Med 2006;355:11-20[PMID:16822992 DOI:10.1056/NEJMoa055531]
11 Sasako M,Sakuramoto S,Katai H,Kinoshita T,Furukawa H,Yamaguchi T,Nashimoto A,Fujii M,Nakajima T,Ohashi Y.Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.J Clin Oncol 2011;29:4387-4393[PMID:22010012 DOI:10.1200/JCO.2011.36.5908]
12 Bang YJ,Kim YW,Yang HK,Chung HC,Park YK,Lee KH,Lee KW,Kim YH,Noh SI,Cho JY,Mok YJ,Kim YH,Ji J,Yeh TS,Button P,Sirzén F,Noh SH.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC):a phase 3open-label,randomised controlled trial.Lancet 2012;379:315-321[PMID:22226517 DOI:10.1016/S0140-6736(11)61873-4]
13 Vanhoefer U,Rougier P,Wilke H,Ducreux MP,Lacave AJ,Van Cutsem E,Planker M,Santos JG,Piedbois P,Paillot B,Bodenstein H,Schmoll HJ,Bleiberg H,Nordlinger B,Couvreur ML,Baron B,Wils JA.Final results of a randomized phase III trial of sequential high-dose methotrexate,fluorouracil,and doxorubicin versus etoposide,leucovorin,and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer:A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.J Clin Oncol2000;18:2648-2657[PMID:10894863]
14 Cunningham D,O kines A F,Ashley S.Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med 2010;362:858-859[PMID:20200397 DOI:10.1056/NEJMc0911925]
15 Van Cutsem E,Moiseyenko VM,Tjulandin S,Majlis A,Constenla M,Boni C,Rodrigues A,Fodor M,Chao Y,Voznyi E,Risse ML,Ajani JA.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group.J Clin Oncol 2006;24:4991-4997[PMID:17075117 DOI:10 .1200/JCO.2006.06.8429]
16 Hironaka S,Ueda S,Yasui H,Nishina T,Tsuda M,Tsumura T,Sugimoto N,Shimodaira H,Tokunaga S,Moriwaki T,Esaki T,Nagase M,Fujitani K,Yamaguchi K,Ura T,Hamamoto Y,Morita S,Okamoto I,Boku N,Hyodo I.Randomized,open-label,phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum:WJOG 4007 trial.J Clin Oncol 2013;31:4438-4444[PMID:24190112 DOI:10.1200/JCO.2012.48.5805]
17 Ford HE,Marshall A,Bridgewater JA,Janowitz T,Coxon FY,Wadsley J,Mansoor W,Fyfe D,Madhusudan S,Middleton GW,Swinson D,Falk S,Chau I,Cunningham D,Kareclas P,Cook N,Blazeby JM,Dunn JA.Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma(COUGAR-02):an open-label,phase 3 randomised controlled trial.Lancet Oncol 2014;15:78-86[PMID:24332238 DOI:10.1016/S1470-2045(13)70549-7]
18 Fuchs CS,Tomasek J,Yong CJ,Dumitru F,Passalacqua R,Goswami C,Safran H,dos Santos LV,Aprile G,Ferry DR,Melichar B,Tehfe M,Topuzov E,Zalcberg JR,Chau I,Campbell W,Sivanandan C,Pikiel J,Koshiji M,Hsu Y,Liepa AM,Gao L,Schwartz JD,Tabernero J.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD):an international,randomised,multicentre,placebo-controlled,phase 3 trial.Lancet 2014;383:31-39[PMID:24094768 DOI:10.1016/S0140-6736(13)61719-5]
19 Wilke H,Muro K,Van Cutsem E,Oh SC,Bodoky G,Shimada Y,Hironaka S,Sugimoto N,Lipatov O,Kim TY,Cunningham D,Rougier P,Komatsu Y,Ajani J,Emig M,Carlesi R,Ferry D,Chandrawansa K,Schwartz JD,Ohtsu A.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(RAINBOW):a double-blind,randomised phase3 trial.Lancet Oncol 2014;15:1224-1235[PMID:25240821 DOI:10 .1016/S1470-2045(14)70420-6]
20 Fuchs CS,Mayer RJ.Gastric carcinoma.N Engl J Med 1995;333:32-41[PMID:7776992 DOI:10.1056/NEJM199507063330107]
21 Parsonnet J,Friedman GD,Orentreich N,Vogelman H.Risk for gastric cancer in people with Cag A positive or Cag A negative Helicobacter pylori infection.Gut 1997;40:297-301[PMID:9135515]
22 Chow WH,Blot WJ,Vaughan TL,Risch HA,Gammon MD,Stanford JL,Dubrow R,Schoenberg JB,Mayne ST,Farrow DC,Ahsan H,West AB,Rotterdam H,Niwa S,Fraumeni JF.Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia.J Natl Cancer Inst 1998;90:150-155[PMID:9450576]
23 Lagergren J,Bergstr?m R,Lindgren A,Nyrén O.Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.N Engl J Med 1999;340:825-831[PMID:10080844 DOI:10.1056/NEJM199903183401101]
24 Nicholson RI,Gee JM,Harper ME.EGFR and cancer prognosis.Eur J Cancer 2001;37 Suppl 4:S9-S15[PMID:11597399]
25 Hudis CA.Trastuzumab--mechanism of action and use in clinical practice.N Engl J Med 2007;357:39-51[PMID:17611206 DOI:10 .1056/NEJMra043186]
26 Sithanandam G,Anderson LM.The ERBB3 receptor in cancer and cancer gene therapy.Cancer Gene Ther 2008;15:413-448[PMID:18404164 DOI:10.1038/cgt.2008.15]
27 Gu J,Zheng L,Wang Y,Zhu M,Wang Q,Li X.Prognostic significance of HER2 expression based on trastuzumab for gastric cancer(To GA)criteria in gastric cancer:an updated meta-analysis.Tumour Biol 2014;35:5315-5321[PMID:24557541 DOI:10 .1007/s13277-014-1693-7]
28 Chen C,Yang JM,Hu TT,Xu TJ,Yan G,Hu SL,Wei W,Xu WP.Prognostic role of human epidermal growth factor receptor in gastric cancer:a systematic review and meta-analysis.Arch Med Res 2013;44:380-389[PMID:23871709 DOI:10.1016/j.arcmed.2013.07.001]
29 Liang JW,Zhang JJ,Zhang T,Zheng ZC.Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer:a meta-analysis of the literature.Tumour Biol 2014;35:4849-4858[PMID:24449506 DOI:10.1007/s13277-014-1636-3]
30 Baselga J,Cortés J,Kim SB,Im SA,Hegg R,Im YH,Roman L,Pedrini JL,Pienkowski T,Knott A,Clark E,Benyunes MC,Ross G,Swain SM.Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.N Engl J Med 2012;366:109-119[PMID:22149875 DOI:10.1056/NEJMoa1113216]
31 Kang YK,Rha SY,Tassone P,Barriuso J,Yu R,Szado T,Garg A,Bang YJ.A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab,capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.Br J Cancer 2014;111:660-666[PMID:24960402 DOI:10.1038/bjc.2014.356]
32 Satoh T,Xu RH,Chung HC,Sun GP,Doi T,Xu JM,Tsuji A,Omuro Y,Li J,Wang JW,Miwa H,Qin SK,Chung IJ,Yeh KH,Feng JF,Mukaiyama A,Kobayashi M,Ohtsu A,Bang YJ.Lapatinib plus paclitaxel versus paclitaxel alone in the secondline treatment of HER2-amplified advanced gastric cancer in Asian populations:Ty TAN--a randomized,phase III study.J Clin Oncol 2014;32:2039-2049[PMID:24868024 DOI:10.1200/JCO.2013.53.6136]
33 Hecht J,Bang Y,Qin S,Chung H,Xu J,Park J,Jeziorski K,Shparyk Y,Hoff P,Sobrero A,Salman P,Li J,Protsenko S,Buyse M,Afenjar K,Kaneko T,Kemner A,Santillana S,Press M,Slamon D.Lapatinib in combination with capecitabine plus oxaliplatin(Cape Ox)in HER2-positive advanced or metastatic gastric,esophageal,or gastroesophageal adenocarcinoma(AC):The TRIO-013/LOGi C Trial.J Clin Oncol 2013;31(Suppl 18):4001
34 Jácome AA,Wohnrath DR,Scapulatempo Neto C,Carneseca EC,Serrano SV,Viana LS,Nunes JS,Martinez EZ,Santos JS.Prognostic value of epidermal growth factor receptors in gastric cancer:a survival analysis by Weibull model incorporating longterm survivors.Gastric Cancer 2014;17:76-86[PMID:23455716DOI:10.1007/s10120-013-0236-z]
35 Begnami MD,Fukuda E,Fregnani JH,Nonogaki S,Montagnini AL,da Costa WL,Soares FA.Prognostic implications of altered human epidermal growth factor receptors(HERs)in gastric carcinomas:HER2 and HER3 are predictors of poor outcome.J Clin Oncol 2011;29:3030-3036[PMID:21709195 DOI:10.1200/JCO.2010.33.6313]
36 Kim MA,Lee HS,Lee HE,Jeon YK,Yang HK,Kim WH.EGFR in gastric carcinomas:prognostic significance of protein overexpression and high gene copy number.Histopathology 2008;52:738-746[PMID:18397279 DOI:10.1111/j.1365-2559.2008.03021.x]
37 Lordick F,Kang YK,Chung HC,Salman P,Oh SC,Bodoky G,Kurteva G,Volovat C,Moiseyenko VM,Gorbunova V,Park JO,Sawaki A,Celik I,G?tte H,MelezínkováH,Moehler M.Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer(EXPAND):a randomised,open-label phase 3 trial.Lancet Oncol 2013;14:490-499[PMID:23594786 DOI:10.1016/S1470-2045(13)70102-5]
38 Waddell T,Chau I,Cunningham D,Gonzalez D,Okines AF,Okines C,Wotherspoon A,Saffery C,Middleton G,Wadsley J,Ferry D,Mansoor W,Crosby T,Coxon F,Smith D,Waters J,Iveson T,Falk S,Slater S,Peckitt C,Barbachano Y.Epirubicin,oxaliplatin,and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer(REAL3):a randomised,open-label phase 3 trial.Lancet Oncol 2013;14:481-489[PMID:23594787 DOI:10.1016/S1470-2045(13)70096-2]
39 Kim Y,Sasaki Y,Lee K,Rha S,Park S,Boku N,Komatsu Y,Kim T,Kim S,Sakata Y.Randomized phase II study of nimotuzumab,an anti-EGFR antibody,plus irinotecan in patients with 5-fluorouracilbased regimen-refractory advanced or recurrent gastric cancer in Korea and Japan:Preliminary results.J Clin Oncol 2011;29(suppl4);87
40 Dragovich T,Mc Coy S,Fenoglio-Preiser CM,Wang J,Benedetti JK,Baker AF,Hackett CB,Urba SG,Zaner KS,Blanke CD,Abbruzzese JL.Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas:SWOG 0127.J Clin Oncol 2006;24:4922-4927[PMID:17050876 DOI:10.1200/JCO.2006.07.1316]
41 Ferrara N,Gerber HP,Le Couter J.The biology of VEGF and its receptors.Nat Med 2003;9:669-676[PMID:12778165 DOI:10 .1038/nm0603-669]
42 Lieto E,Ferraraccio F,Orditura M,Castellano P,Mura AL,Pinto M,Zamboli A,De Vita F,Galizia G.Expression of vascular endothelial growth factor(VEGF)and epidermal growth factor receptor(EGFR)is an independent prognostic indicator of worse outcome in gastric cancer patients.Ann Surg Oncol 2008;15:69-79[PMID:17896140 DOI:10.1245/s10434-007-9596-0]
43 Cabuk D,Basaran G,Celikel C,Dane F,Yumuk PF,Iyikesici MS,Ekenel M,Turhal NS.Vascular endothelial growth factor,hypoxia-inducible factor 1 alpha and CD34 expressions in earlystage gastric tumors:relationship with pathological factors and prognostic impact on survival.Oncology 2007;72:111-117[PMID:18025805 DOI:10.1159/111118]
44 Hurwitz H,Fehrenbacher L,Novotny W,Cartwright T,Hainsworth J,Heim W,Berlin J,Baron A,Griffing S,Holmgren E,Ferrara N,Fyfe G,Rogers B,Ross R,Kabbinavar F.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer.N Engl J Med 2004;350:2335-2342[PMID:15175435 DOI:10.1056/NEJMoa032691]
45 Sandler A,Gray R,Perry MC,Brahmer J,Schiller JH,Dowlati A,Lilenbaum R,Johnson DH.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med 2006;355:2542-2550[PMID:17167137 DOI:10.1056/NEJMoa061884]
46 Miller K,Wang M,Gralow J,Dickler M,Cobleigh M,Perez EA,Shenkier T,Cella D,Davidson NE.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.N Engl J Med 2007;357:2666-2676[PMID:18160686 DOI:10.1056/NEJMoa072113]
47 Friedman HS,Prados MD,Wen PY,Mikkelsen T,Schiff D,Abrey LE,Yung WK,Paleologos N,Nicholas MK,Jensen R,Vredenburgh J,Huang J,Zheng M,Cloughesy T.Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.J Clin Oncol 2009;27:4733-4740[PMID:19720927 DOI:10 .1200/JCO.2008.19.8721]
48 Burger RA,Brady MF,Bookman MA,Fleming GF,Monk BJ,Huang H,Mannel RS,Homesley HD,Fowler J,Greer BE,Boente M,Birrer MJ,Liang SX.Incorporation of bevacizumab in the primary treatment of ovarian cancer.N Engl J Med 2011;365:2473-2483[PMID:22204724 DOI:10.1056/NEJMoa1104390]
49 Perren TJ,Swart AM,Pfisterer J,Ledermann JA,Pujade-Lauraine E,Kristensen G,Carey MS,Beale P,Cervantes A,Kurzeder C,du Bois A,Sehouli J,Kimmig R,St?hle A,Collinson F,Essapen S,Gourley C,Lortholary A,Selle F,Mirza MR,Leminen A,Plante M,Stark D,Qian W,Parmar MK,Oza AM.A phase 3trial of bevacizumab in ovarian cancer.N Engl J Med 2011;365:2484-2496[PMID:22204725 DOI:10.1056/NEJMoa1103799]
50 Tewari KS,Sill MW,Long HJ,Penson RT,Huang H,Ramondetta LM,Landrum LM,Oaknin A,Reid TJ,Leitao MM,Michael HE,Monk BJ.Improved survival with bevacizumab in advanced cervical cancer.N Engl J Med 2014;370:734-743[PMID:24552320 DOI:10.1056/NEJMoa1309748]
51 Shah MA,Ramanathan RK,Ilson DH,Levnor A,D’Adamo D,O’Reilly E,Tse A,Trocola R,Schwartz L,Capanu M,Schwartz GK,Kelsen DP.Multicenter phase II study of irinotecan,cisplatin,and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.J Clin Oncol 2006;24:5201-5206[PMID:17114652 DOI:10.1200/JCO.2006.08.0887]
52 Ohtsu A,Shah MA,Van Cutsem E,Rha SY,Sawaki A,Park SR,Lim HY,Yamada Y,Wu J,Langer B,Starnawski M,Kang YK.Bevacizumab in combination with chemotherapy as firstline therapy in advanced gastric cancer:a randomized,doubleblind,placebo-controlled phase III study.J Clin Oncol 2011;29:3968-3976[PMID:21844504 DOI:10.1200/JCO.2011.36.2236]
53 Yoon H,Johanna C,Braiteh F,Firdaus I,Philip P,Cohn A,Lewis N,Anderson D,Arrowsmith E,Schwartz J,Xu Y,Koshiji M,Alberts S,Wainberg Z.Ramucirumab(RAM)plus FOLFOX as front-line therapy(Rx)for advanced gastric or esophageal adenocarcinoma(GE-AC):Randomized,double-blind,multicenter phase 2 trial.J Clin Oncol 2014;32(Suppl 15):4004
54 Qin S.Phase III study of apatinib in advanced gastric cancer:A randomized,double-blind,placebo-controlled trial.J Clin Oncol2014;32(Suppl 15):4003
55 Jia S,Liu Z,Zhang S,Liu P,Zhang L,Lee SH,Zhang J,Signoretti S,Loda M,Roberts TM,Zhao JJ.Essential roles of PI(3)K-p110beta in cell growth,metabolism and tumorigenesis.Nature 2008;454:776-779[PMID:18594509 DOI:10.1038/nature07091]
56 Byun DS,Cho K,Ryu BK,Lee MG,Park JI,Chae KS,Kim HJ,Chi SG.Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.Int J Cancer 2003;104:318-327[PMID:12569555 DOI:10.1002/ijc.10962]
57 Li VS,Wong CW,Chan TL,Chan AS,Zhao W,Chu KM,So S,Chen X,Yuen ST,Leung SY.Mutations of PIK3CA in gastric adenocarcinoma.BMC Cancer 2005;5:29[PMID:15784156DOI:10.1186/1471-2407-5-29]
58 Velho S,Oliveira C,Ferreira A,Ferreira AC,Suriano G,Schwartz S,Duval A,Carneiro F,Machado JC,Hamelin R,Seruca R.The prevalence of PIK3CA mutations in gastric and colon cancer.Eur J Cancer 2005;41:1649-1654[PMID:15994075 DOI:10.1016/j.ejca.2005.04.022]
59 Zhou J,Chen GB,Tang YC,Sinha RA,Wu Y,Yap CS,Wang G,Hu J,Xia X,Tan P,Goh LK,Yen PM.Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library.BMC Med Genomics 2012;5:34[PMID:22876838 DOI:10 .1186/1755-8794-5-34]
60 Lang SA,Gaumann A,Koehl GE,Seidel U,Bataille F,Klein D,Ellis LM,Bolder U,Hofstaedter F,Schlitt HJ,Geissler EK,Stoeltzing O.Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.Int J Cancer 2007;120:1803-1810[PMID:17230506 DOI:10.1002/ijc.22442]
61 Ohtsu A,Ajani JA,Bai YX,Bang YJ,Chung HC,Pan HM,Sahmoud T,Shen L,Yeh KH,Chin K,Muro K,Kim YH,Ferry D,Tebbutt NC,Al-Batran SE,Smith H,Costantini C,Rizvi S,Lebwohl D,Van Cutsem E.Everolimus for previously treated advanced gastric cancer:results of the randomized,double-blind,phase III GRANITE-1 study.J Clin Oncol 2013;31:3935-3943[PMID:24043745 DOI:10.1200/JCO.2012.48.3552]
62 Blume-Jensen P,Hunter T.Oncogenic kinase signalling.Nature2001;411:355-365[PMID:11357143 DOI:10.1038/35077225]
63 Xie L,Su X,Zhang L,Yin X,Tang L,Zhang X,Xu Y,Gao Z,Liu K,Zhou M,Gao B,Shen D,Zhang L,Ji J,Gavine PR,Zhang J,Kilgour E,Zhang X,Ji Q.FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.Clin Cancer Res 2013;19:2572-2583[PMID:23493349DOI:10.1158/1078-0432.CCR-12-3898]
64 Su X,Zhan P,Gavine PR,Morgan S,Womack C,Ni X,Shen D,Bang YJ,Im SA,Ho Kim W,Jung EJ,Grabsch HI,Kilgour E.FGFR2 amplification has prognostic significance in gastric cancer:results from a large international multicentre study.Br J Cancer2014;110:967-975[PMID:24457912 DOI:10.1038/bjc.2013.802]
65 Jung EJ,Jung EJ,Min SY,Kim MA,Kim WH.Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma.Hum Pathol 2012;43:1559-1566[PMID:22440694 DOI:10.1016/j.humpath.2011.12.002]
66 Gozgit JM,Wong MJ,Moran L,Wardwell S,Mohemmad QK,Narasimhan NI,Shakespeare WC,Wang F,Clackson T,Rivera VM.Ponatinib(AP24534),a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.Mol Cancer Ther 2012;11:690-699[PMID:22238366DOI:10.1158/1535-7163.MCT-11-0450]
67 Deng N,Goh LK,Wang H,Das K,Tao J,Tan IB,Zhang S,Lee M,Wu J,Lim KH,Lei Z,Goh G,Lim QY,Tan AL,Sin Poh DY,Riahi S,Bell S,Shi MM,Linnartz R,Zhu F,Yeoh KG,Toh HC,Yong WP,Cheong HC,Rha SY,Boussioutas A,Grabsch H,Rozen S,Tan P.A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.Gut 2012;61:673-684[PMID:22315472 DOI:10.1136/gutjnl-2011-301839]
68 Bang YJ,Van Cutsem E,Mansoor W,Petty R,Chao Y,Cunningham D,Ferry D,Landers D,Stockman P,Smith N,Geh C,Kilgour E.A randomized,open-label phase II study of AZD4547(AZD)versus Paclitaxel(P)in previously treated patients with advanced gastric cancer(AGC)with Fibroblast Growth Factor Receptor 2(FGFR2)polysomy or gene amplification(amp):SHINE study.J Clin Oncol 2015;33(Suppl 20):4014
69 Kiyose S,Nagura K,Tao H,Igarashi H,Yamada H,Goto M,Maeda M,Kurabe N,Suzuki M,Tsuboi M,Kahyo T,Shinmura K,Hattori N,Sugimura H.Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization.Pathol Int 2012;62:477-484[PMID:22691185 DOI:10.1111/j.1440-1827.2012.02832.x]
70 Lennerz JK,Kwak EL,Ackerman A,Michael M,Fox SB,Bergethon K,Lauwers GY,Christensen JG,Wilner KD,Haber DA,Salgia R,Bang YJ,Clark JW,Solomon BJ,Iafrate AJ.MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.J Clin Oncol 2011;29:4803-4810[PMID:22042947DOI:10.1200/JCO.2011.35.4928]
71 Shah MA,Wainberg ZA,Catenacci DV,Hochster HS,Ford J,Kunz P,Lee FC,Kallender H,Cecchi F,Rabe DC,Keer H,Martin AM,Liu Y,Gagnon R,Bonate P,Liu L,Gilmer T,Bottaro DP.Phase II study evaluating 2 dosing schedules of oral foretinib(GSK1363089),c MET/VEGFR2 inhibitor,in patients with metastatic gastric cancer.PLo S One 2013;8:e54014[PMID:23516391 DOI:10.1371/journal.pone.0054014]
72 Shah M,Bang Y,Lordick F,Tabernero J,Chen M,Hack S,Phan S,Shames D,Cunningham D.METGastric:A phase III study of onartuzumab plus m FOLFOX6 in patients with metastatic HER2-negative(HER2-)and MET-positive(MET)adenocarcinoma of the stomach or gastroesophageal junction(GEC).J Clin Oncol2015;33(Suppl 15):4012
73 Iveson T,Donehower RC,Davidenko I,Tjulandin S,Deptala A,Harrison M,Nirni S,Lakshmaiah K,Thomas A,Jiang Y,Zhu M,Tang R,Anderson A,Dubey S,Oliner KS,Loh E.Rilotumumab in combination with epirubicin,cisplatin,and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma:an open-label,dose de-escalation phase 1b study and a double-blind,randomised phase 2 study.Lancet Oncol 2014;15:1007-1018[PMID:24965569 DOI:10.1016/S1470-2045(14)70023-3]
74 Cunningham D,Tebbutt N,Davidenko I,Murad M,Al-Batran S,Ilson D,Tjulandin S,Gotovkin E,Karaszewska B,Bondarenko I,Tejani M,Udrea A,Tehfe M,Baker N,Oliner K,Zhang Y,Hoang T,R S,Catenacci D.Phase III,randomized,double-blind,multicenter,placebo(P)-controlled trial of rilotumumab(R)plus epirubicin,cisplatin and capecitabine(ECX)as first-line therapy in patients(pts)with advanced MET-positive(pos)gastric or gastroesophageal junction(G/GEJ)cancer:RILOMET-1 study.J Clin Oncol 2015;33 (Suppl 15):4000
75 Malka D,Castan F,Francois E,Bouche O,Bennouna J,Ghiringhelli F,De La Fouchardiere C,Borg C,Samalin E,Bachet J,Raoul J,Cvitkovic F,Miglianico L,Bengrine-Lefevre L,Dahan L,Lecaille C,Aparicio T,Perrier H,Gourgou S,Taieb J.FOLFOX alone or combined to rilotumumab or panitumumab as firstline treatment in patients(pts)with advanced gastroesophageal adenocarcinoma(AGEA):An open-label,randomized phase II trial(PRODIGE 17 ACCORD 20 MEGA).J Clin Oncol 2015;33(Suppl15):4016
76 Kang YK,Muro K,Ryu MH,Yasui H,Nishina T,Ryoo BY,Kamiya Y,Akinaga S,Boku N.A phase II trial of a selective c-Met inhibitor tivantinib(ARQ 197)monotherapy as a second-or thirdline therapy in the patients with metastatic gastric cancer.Invest New Drugs 2014;32:355-361[PMID:24337769 DOI:10.1007/s10637-013-0057-2]
77 Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer 2012;12:252-264[PMID:22437870 DOI:10.1038/nrc3239]
78 Hodi FS,O’Day SJ,Mc Dermott DF,Weber RW,Sosman JA,Haanen JB,Gonzalez R,Robert C,Schadendorf D,Hassel JC,Akerley W,van den Eertwegh AJ,Lutzky J,Lorigan P,Vaubel JM,Linette GP,Hogg D,Ottensmeier CH,LebbéC,Peschel C,Quirt I,Clark JI,Wolchok JD,Weber JS,Tian J,Yellin MJ,Nichol GM,Hoos A,Urba WJ.Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med 2010;363:711-723[PMID:20525992 DOI:10.1056/NEJMoa1003466]
79 Hamid O,Robert C,Daud A,Hodi FS,Hwu WJ,Kefford R,Wolchok JD,Hersey P,Joseph RW,Weber JS,Dronca R,Gangadhar TC,Patnaik A,Zarour H,Joshua AM,Gergich K,Elassaiss-Schaap J,Algazi A,Mateus C,Boasberg P,Tumeh PC,Chmielowski B,Ebbinghaus SW,Li XN,Kang SP,Ribas A.Safety and tumor responses with lambrolizumab(anti-PD-1)in melanoma.N Engl J Med 2013;369:134-144[PMID:23724846DOI:10.1056/NEJMoa1305133]
80 Robert C,Long GV,Brady B,Dutriaux C,Maio M,Mortier L,Hassel JC,Rutkowski P,Mc Neil C,Kalinka-Warzocha E,Savage KJ,Hernberg MM,LebbéC,Charles J,Mihalcioiu C,ChiarionSileni V,Mauch C,Cognetti F,Arance A,Schmidt H,Schadendorf D,Gogas H,Lundgren-Eriksson L,Horak C,Sharkey B,Waxman IM,Atkinson V,Ascierto PA.Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med 2015;372:320-330[PMID:25399552 DOI:10.1056/NEJMoa1412082]
81 Qing Y,Li Q,Ren T,Xia W,Peng Y,Liu GL,Luo H,Yang YX,Dai XY,Zhou SF,Wang D.Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer.Drug Des Devel Ther 2015;9:901-909[PMID:25733810 DOI:10 .2147/DDDT.S75152]
82 Wu C,Zhu Y,Jiang J,Zhao J,Zhang XG,Xu N.Immunohistochemical localization of programmed death-1 ligand-1(PD-L1)in gastric carcinoma and its clinical significance.Acta Histochem 2006;108:19-24[PMID:16530813 DOI:10.1016/j.acthis.2006.01.003]
83 Sun J,Xu K,Wu C,Wang Y,Hu Y,Zhu Y,Chen Y,Shi Q,Yu G,Zhang X.PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies.Tissue Antigens 2007;69:19-27[PMID:17212704 DOI:10.1111/j.1399-0039.2006.00701.x]
84 Muro K,Bang Y,Shankaran V,Geva R,Catenacci D,Gupta S,Eder J,Berger R,Gonzalez E,Pulini J,Ray A,Dolled-Filhart M,Emancipator K,Pathiraja K,Shu X,Koshiji M,Cheng J,Chung H.A phase Ib study of pembrolizumab(Pembro;MK-3475)in patients(Pts)with advanced gastric cancer.Ann Oncol 2014;25:1-41[DOI:10.1093/annonc/mdu438]
85 Kralovics R,Passamonti F,Buser AS,Teo SS,Tiedt R,Passweg JR,Tichelli A,Cazzola M,Skoda RC.A gain-of-function mutation of JAK2 in myeloproliferative disorders.N Engl J Med 2005;352:1779-1790[PMID:15858187 DOI:10.1056/NEJMoa051113]
86 Levine RL,Pardanani A,Tefferi A,Gilliland DG.Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.Nat Rev Cancer 2007;7:673-683[PMID:17721432 DOI:10.1038/nrc2210]
87 Judd LM,Menheniott TR,Ling H,Jackson CB,Howlett M,Kalantzis A,Priebe W,Giraud AS.Inhibition of the JAK2/STAT3pathway reduces gastric cancer growth in vitro and in vivo.PLo S One 2014;9:e95993[PMID:24804649 DOI:10.1371/journal.pone.0095993]
88 Ledermann J,Harter P,Gourley C,Friedlander M,Vergote I,Rustin G,Scott C,Meier W,Shapira-Frommer R,Safra T,Matei D,Macpherson E,Watkins C,Carmichael J,Matulonis U.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.N Engl J Med 2012;366:1382-1392[PMID:22452356 DOI:10 .1056/NEJMoa1105535]
89 Oza AM,Cibula D,Benzaquen AO,Poole C,Mathijssen RH,Sonke GS,Colombo N,?pa?ek J,Vuylsteke P,Hirte H,Mahner S,Plante M,Schmalfeldt B,Mackay H,Rowbottom J,Lowe ES,Dougherty B,Barrett JC,Friedlander M.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer:a randomised phase 2 trial.Lancet Oncol 2015;16:87-97[PMID:25481791 DOI:10.1016/S1470-2045(14)71135-0]
90 O’Shaughnessy J,Osborne C,Pippen JE,Yoffe M,Patt D,Rocha C,Koo IC,Sherman BM,Bradley C.Iniparib plus chemotherapy in metastatic triple-negative breast cancer.N Engl J Med 2011;364:205-214[PMID:21208101 DOI:10.1056/NEJMoa1011418]